PSA screening for prostate cancer saves lives after all, study says
After years of growing doubt about the value of screening men for prostate cancer, a new analysis of existing clinical trial evidence has found that when men between 55 and 70 get the prostate-specific antigen, or PSA, test, the result is lives saved.
In 2009, a New England Journal of Medicine editorialist famously called the debate over PSA testing for prostate cancer "the controversy that refuses to die." That comment came with the publication of two clinical trials - one conducted in the United States, the second in Europe
